Literature DB >> 10524669

Human papillomavirus cervical infection and associated risk factors in a region of Argentina with a high incidence of cervical carcinoma.

S A Tonon1, M A Picconi, J B Zinovich, D J Liotta, P D Bos, J A Galuppo, L V Alonio, J A Ferreras, A R Teyssié.   

Abstract

OBJECTIVE: To assess the prevalence and potential risk factors associated with human papillomavirus (HPV) cervical infection among women residing in a region of northeastern Argentina with a high incidence of cervical cancer.
METHODS: A case-control study of 330 women participating in a cervical cytological screening program conducted in Posadas city, Misiones, Argentina, from February 1997 to November 1998 was carried out. Standardized questionnaires were administered, and clinical examination including colposcopy was performed. Fresh endocervical specimens for HPV DNA detection by generic polymerase chain reaction were collected and the products typed by dot-blot hybridization.
RESULTS: Human papillomavirus DNA was found in 61% of samples analyzed (185/301). Samples with normal cytology had a 43% infection rate (85/199), while those classified as low-grade squamous intraepithelial lesion, high-grade squamous intraepithelial lesion, and invasive cervical carcinoma had an infection rate of 96% (53/55), 100% (29/29), and 100% (18/18), respectively. Human papillomavirus typing showed a 64% (118/185) prevalence of type 16 among all the infected population analyzed; type 16 was detected among 49% (42/85) of infected samples with normal cytology and in an average of 74% (74/100) with abnormal cytology. Sexual behavior, residence in southern Paraguay, and history of a previous sexually transmitted diseases were the main risk factors associated with high-grade cervical lesions.
CONCLUSIONS: An elevated prevalence of HPV infection was detected in this population, which also has a high incidence of cervical cancer. The broad distribution of high-risk HPV type 16 in women with normal cytology and colposcopy suggests that viral infection is an important determinant of regional cancer incidence.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10524669      PMCID: PMC1784749          DOI: 10.1002/(SICI)1098-0997(1999)7:5<237::AID-IDOG6>3.0.CO;2-4

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  19 in total

Review 1.  Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia.

Authors:  M H Schiffman
Journal:  J Natl Cancer Inst       Date:  1992-03-18       Impact factor: 13.506

2.  Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia.

Authors:  A J Van Den Brule; J M Walboomers; M Du Maine; P Kenemans; C J Meijer
Journal:  Int J Cancer       Date:  1991-05-30       Impact factor: 7.396

3.  The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR.

Authors:  A M de Roda Husman; J M Walboomers; A J van den Brule; C J Meijer; P J Snijders
Journal:  J Gen Virol       Date:  1995-04       Impact factor: 3.891

4.  Statistical methods in cancer research. Volume I - The analysis of case-control studies.

Authors:  N E Breslow; N E Day
Journal:  IARC Sci Publ       Date:  1980

5.  Epidemiologic correlates of cervical neoplasia and risk of human papillomavirus infection in asymptomatic women in Brazil.

Authors:  L L Villa; E L Franco
Journal:  J Natl Cancer Inst       Date:  1989-03-01       Impact factor: 13.506

6.  The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain.

Authors:  N Muñoz; F X Bosch; S de Sanjosé; L Tafur; I Izarzugaza; M Gili; P Viladiu; C Navarro; C Martos; N Ascunce
Journal:  Int J Cancer       Date:  1992-11-11       Impact factor: 7.396

Review 7.  Human papillomaviruses in the pathogenesis of anogenital cancer.

Authors:  H zur Hausen
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

8.  A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.

Authors:  L A Koutsky; K K Holmes; C W Critchlow; C E Stevens; J Paavonen; A M Beckmann; T A DeRouen; D A Galloway; D Vernon; N B Kiviat
Journal:  N Engl J Med       Date:  1992-10-29       Impact factor: 91.245

9.  Detection of HPV-DNA in semen, urine and urethral samples by dot blot and PCR.

Authors:  G Astori; C Pipan; G Muffato; G A Botta
Journal:  New Microbiol       Date:  1995-04       Impact factor: 2.479

10.  Human papillomavirus, herpes simplex virus and other potential risk factors for cervical cancer in a high-risk area (Greenland) and a low-risk area (Denmark)--a second look.

Authors:  S K Kjaer; E M de Villiers; H Cağlayan; E Svare; B J Haugaard; G Engholm; R B Christensen; K A Møller; P Poll; H Jensen
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

View more
  3 in total

Review 1.  Type-specific HPV prevalence in cervical cancer and high-grade lesions in Latin America and the Caribbean: systematic review and meta-analysis.

Authors:  Agustín Ciapponi; Ariel Bardach; Demián Glujovsky; Luz Gibbons; María Alejandra Picconi
Journal:  PLoS One       Date:  2011-10-04       Impact factor: 3.240

2.  Lifestyle and socio-demographic factors associated with high-risk HPV infection in UK women.

Authors:  S C Cotton; L Sharp; R Seth; L F Masson; J Little; M E Cruickshank; K Neal; N Waugh
Journal:  Br J Cancer       Date:  2007-05-22       Impact factor: 7.640

Review 3.  New Insights in the Pathogenesis of HPV Infection and the Associated Carcinogenic Processes: The Role of Chronic Inflammation and Oxidative Stress.

Authors:  Simona Roxana Georgescu; Cristina Iulia Mitran; Madalina Irina Mitran; Constantin Caruntu; Maria Isabela Sarbu; Clara Matei; Ilinca Nicolae; Sandra Milena Tocut; Mircea Ioan Popa; Mircea Tampa
Journal:  J Immunol Res       Date:  2018-08-27       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.